Hdac Inhibitor Cxd101 Uses, Dosage, Side Effects and more
Hdac Inhibitor Cxd101 is under investigation in clinical trial NCT03873025 (A Study of Hdac Inhibitor Cxd101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
| Trade Name | Hdac Inhibitor Cxd101 |
| Generic | CXD101 |
| CXD101 Other Names | Hdac inhibitor cxd101, Hdac-in-4 |
| Type | |
| Formula | C24H29N5O |
| Weight | Average: 403.53 Monoisotopic: 403.237210574 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
